Clinical Features and Treatment Outcome of Malignant Pleural Mesothelioma

Manlio Mencoboni, Rosa A. Filiberti, Paola Taveggia, Federica Grosso, Giulia Pasello, Lisette Del Corso, Alberto Muzio, Valentina Polo, Paolo Zucali, Giovanni L. Ceresoli, Hector J. Soto Parra, Laura Auriati, Claudio Simonassi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Malignant pleural mesothelioma is a problematic condition due to poor prognosis and difficulties in management. We evaluated the treatment and outcome of 378 mesothelioma patients referred to 6 Italian Oncology Departments. Methods: Demographic and clinical data were collected. Treatment was assessed in terms of chemotherapy (line of treatment, pemetrexed-based regimen, other therapies), surgery, and radiotherapy. Response to therapy, progression-free survival, and overall survival were evaluated. Results: 36 and 342 patients received best supportive care and active treatment, respectively; 86 patients underwent surgery, and 26 received trimodal therapy. Disease control after first-line chemotherapy was achieved in 74.2% of patients (75.7% in patients treated with pemetrexed combined with other drugs and 69% with pemetrexed as monotherapy). The disease control rate was 82.6% in pemetrexed re-challenged individuals. Median survival time was 11.6 months with supportive care, 16.2 months with chemotherapy only, 32.4 months with surgery plus chemotherapy, and 47.2 months with trimodal therapy. A more favorable prognosis was observed in responders to first-line therapy who were then actively treated with second-line (24.8 vs. 11.8 months in non-responders, p < 0.001) and third-line chemotherapy (28.9 vs. 17.8 months in non-responders, p = 0.005). Conclusion: Mesothelioma patients benefited from chemotherapy alone only when retreated in the second line after response to first-line therapy.

Original languageEnglish
Pages (from-to)364-369
Number of pages6
JournalOncology Research and Treatment
Volume40
Issue number6
DOIs
Publication statusPublished - Jun 1 2017

Fingerprint

Pemetrexed
Drug Therapy
Therapeutics
Mesothelioma
Malignant Mesothelioma
Survival
Disease-Free Survival
Radiotherapy
Demography
Pharmaceutical Preparations

Keywords

  • Chemotherapy
  • Malignant pleural mesothelioma
  • Response
  • Surgery
  • Survival

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Clinical Features and Treatment Outcome of Malignant Pleural Mesothelioma. / Mencoboni, Manlio; Filiberti, Rosa A.; Taveggia, Paola; Grosso, Federica; Pasello, Giulia; Del Corso, Lisette; Muzio, Alberto; Polo, Valentina; Zucali, Paolo; Ceresoli, Giovanni L.; Soto Parra, Hector J.; Auriati, Laura; Simonassi, Claudio.

In: Oncology Research and Treatment, Vol. 40, No. 6, 01.06.2017, p. 364-369.

Research output: Contribution to journalArticle

Mencoboni, M, Filiberti, RA, Taveggia, P, Grosso, F, Pasello, G, Del Corso, L, Muzio, A, Polo, V, Zucali, P, Ceresoli, GL, Soto Parra, HJ, Auriati, L & Simonassi, C 2017, 'Clinical Features and Treatment Outcome of Malignant Pleural Mesothelioma', Oncology Research and Treatment, vol. 40, no. 6, pp. 364-369. https://doi.org/10.1159/000464410
Mencoboni, Manlio ; Filiberti, Rosa A. ; Taveggia, Paola ; Grosso, Federica ; Pasello, Giulia ; Del Corso, Lisette ; Muzio, Alberto ; Polo, Valentina ; Zucali, Paolo ; Ceresoli, Giovanni L. ; Soto Parra, Hector J. ; Auriati, Laura ; Simonassi, Claudio. / Clinical Features and Treatment Outcome of Malignant Pleural Mesothelioma. In: Oncology Research and Treatment. 2017 ; Vol. 40, No. 6. pp. 364-369.
@article{7f53ce2c955e416b84c22f3e4a0c2591,
title = "Clinical Features and Treatment Outcome of Malignant Pleural Mesothelioma",
abstract = "Background: Malignant pleural mesothelioma is a problematic condition due to poor prognosis and difficulties in management. We evaluated the treatment and outcome of 378 mesothelioma patients referred to 6 Italian Oncology Departments. Methods: Demographic and clinical data were collected. Treatment was assessed in terms of chemotherapy (line of treatment, pemetrexed-based regimen, other therapies), surgery, and radiotherapy. Response to therapy, progression-free survival, and overall survival were evaluated. Results: 36 and 342 patients received best supportive care and active treatment, respectively; 86 patients underwent surgery, and 26 received trimodal therapy. Disease control after first-line chemotherapy was achieved in 74.2{\%} of patients (75.7{\%} in patients treated with pemetrexed combined with other drugs and 69{\%} with pemetrexed as monotherapy). The disease control rate was 82.6{\%} in pemetrexed re-challenged individuals. Median survival time was 11.6 months with supportive care, 16.2 months with chemotherapy only, 32.4 months with surgery plus chemotherapy, and 47.2 months with trimodal therapy. A more favorable prognosis was observed in responders to first-line therapy who were then actively treated with second-line (24.8 vs. 11.8 months in non-responders, p < 0.001) and third-line chemotherapy (28.9 vs. 17.8 months in non-responders, p = 0.005). Conclusion: Mesothelioma patients benefited from chemotherapy alone only when retreated in the second line after response to first-line therapy.",
keywords = "Chemotherapy, Malignant pleural mesothelioma, Response, Surgery, Survival",
author = "Manlio Mencoboni and Filiberti, {Rosa A.} and Paola Taveggia and Federica Grosso and Giulia Pasello and {Del Corso}, Lisette and Alberto Muzio and Valentina Polo and Paolo Zucali and Ceresoli, {Giovanni L.} and {Soto Parra}, {Hector J.} and Laura Auriati and Claudio Simonassi",
year = "2017",
month = "6",
day = "1",
doi = "10.1159/000464410",
language = "English",
volume = "40",
pages = "364--369",
journal = "Oncology Research and Treatment",
issn = "2296-5270",
publisher = "S. Karger AG",
number = "6",

}

TY - JOUR

T1 - Clinical Features and Treatment Outcome of Malignant Pleural Mesothelioma

AU - Mencoboni, Manlio

AU - Filiberti, Rosa A.

AU - Taveggia, Paola

AU - Grosso, Federica

AU - Pasello, Giulia

AU - Del Corso, Lisette

AU - Muzio, Alberto

AU - Polo, Valentina

AU - Zucali, Paolo

AU - Ceresoli, Giovanni L.

AU - Soto Parra, Hector J.

AU - Auriati, Laura

AU - Simonassi, Claudio

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Background: Malignant pleural mesothelioma is a problematic condition due to poor prognosis and difficulties in management. We evaluated the treatment and outcome of 378 mesothelioma patients referred to 6 Italian Oncology Departments. Methods: Demographic and clinical data were collected. Treatment was assessed in terms of chemotherapy (line of treatment, pemetrexed-based regimen, other therapies), surgery, and radiotherapy. Response to therapy, progression-free survival, and overall survival were evaluated. Results: 36 and 342 patients received best supportive care and active treatment, respectively; 86 patients underwent surgery, and 26 received trimodal therapy. Disease control after first-line chemotherapy was achieved in 74.2% of patients (75.7% in patients treated with pemetrexed combined with other drugs and 69% with pemetrexed as monotherapy). The disease control rate was 82.6% in pemetrexed re-challenged individuals. Median survival time was 11.6 months with supportive care, 16.2 months with chemotherapy only, 32.4 months with surgery plus chemotherapy, and 47.2 months with trimodal therapy. A more favorable prognosis was observed in responders to first-line therapy who were then actively treated with second-line (24.8 vs. 11.8 months in non-responders, p < 0.001) and third-line chemotherapy (28.9 vs. 17.8 months in non-responders, p = 0.005). Conclusion: Mesothelioma patients benefited from chemotherapy alone only when retreated in the second line after response to first-line therapy.

AB - Background: Malignant pleural mesothelioma is a problematic condition due to poor prognosis and difficulties in management. We evaluated the treatment and outcome of 378 mesothelioma patients referred to 6 Italian Oncology Departments. Methods: Demographic and clinical data were collected. Treatment was assessed in terms of chemotherapy (line of treatment, pemetrexed-based regimen, other therapies), surgery, and radiotherapy. Response to therapy, progression-free survival, and overall survival were evaluated. Results: 36 and 342 patients received best supportive care and active treatment, respectively; 86 patients underwent surgery, and 26 received trimodal therapy. Disease control after first-line chemotherapy was achieved in 74.2% of patients (75.7% in patients treated with pemetrexed combined with other drugs and 69% with pemetrexed as monotherapy). The disease control rate was 82.6% in pemetrexed re-challenged individuals. Median survival time was 11.6 months with supportive care, 16.2 months with chemotherapy only, 32.4 months with surgery plus chemotherapy, and 47.2 months with trimodal therapy. A more favorable prognosis was observed in responders to first-line therapy who were then actively treated with second-line (24.8 vs. 11.8 months in non-responders, p < 0.001) and third-line chemotherapy (28.9 vs. 17.8 months in non-responders, p = 0.005). Conclusion: Mesothelioma patients benefited from chemotherapy alone only when retreated in the second line after response to first-line therapy.

KW - Chemotherapy

KW - Malignant pleural mesothelioma

KW - Response

KW - Surgery

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=85018935573&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018935573&partnerID=8YFLogxK

U2 - 10.1159/000464410

DO - 10.1159/000464410

M3 - Article

AN - SCOPUS:85018935573

VL - 40

SP - 364

EP - 369

JO - Oncology Research and Treatment

JF - Oncology Research and Treatment

SN - 2296-5270

IS - 6

ER -